ANIL KUMAR YADAV

Managed Product Portfolio of INR 540+ Cr

• Conducted primary market research and competitor analysis through fieldwork surveys and focus group meetings, extracting customer insights to inform product decisions.
• Performed secondary market analysis of therapy segments using sources such as AIOCD and IQVIA.
• Executed customer segmentation and targeting with customized positioning and marketing strategies tailored to each segment.
• Developed product strategies aligned with market demand and organizational objectives.
• Successfully managed multiple physical and digital projects through omnichannel marketing.
• Leveraged data analytics to measure and analyze project metrics, driving data-informed strategy refinements and ensuring compliance adherence.
• Generated and presented monthly reports on active projects and assignment statuses to management.
• Collaborated cross-functionally with sales and medical affairs teams to align strategies and ensure effective execution.
• Successful launched brand extensions of Telmikind (Telmikind LNB & Telmikind MCT)
• Conducted market projections and brand forecasting to maintain inventory across the supply chain.
• Planned trade stock and promotions to optimize product availability.
• Therapy knowledge for effective portfolio management.
• Conducted routine training sessions for medical representatives for therapy and product knowledge.
• Program Management for National and Zonal Scientific CMEs.

Projects:

• Real India Study (PMS) & TRUST Study (Telmikind),
• LMS Development Projects: ICC HF Credentials, Hriday Panchayat, BP-Sugar, ACC-NYCS (PG Course in Advance Cardiology), Global Connect.
• Corporate Initiatives: DMF (end to end for my division), ABDM (Ayushman Bharat Digital Mission), World Heart Month Campaign, World Hypertension Month Campaign
• Patient Awareness Initiatives: BP Ghatao Life Bhadhao, Old Age Home Campaign, Hriday Panchayat, HF Camp, and Digital BP Camp (SOP and collateral planning),
• CME: CardioQuest (Young Cardios Journal Club) Telmikind (National Advisory Meetings), Hospital Departmental Meets.

Business Impact:

• Brand value and growth in the Last 2 Financial Years: ~444 Cr (26%) ~ 538 Cr (21%)
• 94 Cr. Value jump for group through additional project during 2023-24.

Effectively handled the promotion of products (Januvia & Janumet) through stakeholder management.

• Effectively handled the promotion of existing products (Vaxiflu-4, Zyvac TCV, Twinrab & Vaxirab) through stakeholder management.
• Represented Zydus-Vaxxicare at Pedicon’22
• Won SFE Parameters Champion & Brand champion awards at Zydus Annual meet.

Responsible for the sales of Medical Equipments.

• Reached out to potential customers by phoning, emailing and visiting, using excellent sales techniques to secure leads
• Secured PPO (Pre Placement Offer).

• Drug dispensing, Data management, Prescription & Stock handling.